Why Is Inherited Rare Disease Focused-Larimar Therapeutics Stock Trading Lower Today?
Explore Larimar Therapeutics' 2 study on nomlabofusp for Friedreich's ataxia. Topline data, increased FXN levels, and FDA discussions for accelerated approval.